linjc16/ctgov huggingface dataset:
Living With Fibromyalgia: Triggers,Subgroups, and a Cognitive-Behavioral and Interactive Technology-Based Intervention

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to conduct semi-structured qualitative interviews to examine the personal experiences of women living with fibromyalgia. The specific aims of this study are to identify clinically relevant triggers of fibromyalgia symptoms and examine their impact on activity limitations and participation restrictions.

Detailed Description
-----------------
Fibromyalgia (FM) may currently be the most common rheumatic diagnosis of rheumatologists among their female patients, with 15-20% of all new rheumatology referrals meeting the 1990 American College of Rheumatology (ACR) diagnosis criteria for fibromyalgia. People with fibromyalgia live through widespread musculoskeletal chronic pain, fatigue, psychological distress, and exhibit diminished physical performance due in part to the cycle of pain that adversely affect their activity participation and overall well-being. The purpose of this prospective mixed methods study is to conduct semi-structured qualitative interviews using ethnographic techniques to examine the personal experiences of women living with fibromyalgia. The specific aims of this study are to identify clinically relevant triggers of fibromyalgia symptoms and examine their impact on activity limitations and participation restrictions.

Official Title
-----------------
Living With Fibromyalgia (FM): Triggers,Clinical Subgroups, and the Effects Of A Self-Monitored Cognitive-Behavioral and Interactive Technology-Based Intervention on Clinical Subgroups

Conditions
-----------------
Fibromyalgia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (1)At least 18 years of age; (2) meet the American College of Rheumatology (ACR) criteria for FM as diagnosed by a physician; (3) have been diagnosed with FM at least 1 year prior to admission to the study; (4) have sufficient vision, based on a functional vision test (i.e., read newsprint) to operate a computer program; (5) speak English; and (6) have a private telephone line. Exclusion Criteria: (1)Living beyond a 40-mile radius from the Oakland campus of the University of Pittsburgh. (2)Disability in everyday tasks related to a diagnosis other than FM (e.g., stroke, Parkinson disease) will also be grounds for exclusion.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
qualitative interview, symptom triggers, activity and participation
Laryngeal Disorders and GERD in Assiut University

Study Overview
=================
Brief Summary
-----------------
Study laryngeal disorders by laryngoscopic examination by two physicians on GERD patients diagnosed by gastroenterology department by endoscopy and effect of GERD treatment for 3 months on these laryngeal disorders without any treatment to laryngeal disorders

Official Title
-----------------
Prevalence of Laryngeal Disorders in Patients With GERD in Assiut University Hospital

Conditions
-----------------
Laryngeal Disease

Intervention / Treatment
-----------------
* Device: Laryngoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed GERD by gastroenterology department before start of treatment and have laryngeal symptoms Exclusion Criteria: voice abusers as singers ,teachers and readers.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Laryngoscopy|Laryngoscopic examination of patients with GERD by two physicians|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of laryngeal disorders in GERD patients | Laryngoscopic examination of patients with GERD by two otorhinolaryngologist physicians | One year from February 2020 to February 2021 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of treatment of GERD on these laryngeal disorders | Treatment of GERD by gastroenterology department for 3 months and reexamination of patients by laryngoscopy for laryngeal disorders without any treatment to laryngeal disorders | 3 months |
A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion

Study Overview
=================
Brief Summary
-----------------
This study is not being conducted in the United States. The purpose of the study is to evaluate the effects of nateglinide compared to glibenclamide on renal hemodynamics and albumin excretion.

Official Title
-----------------
A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion

Conditions
-----------------
Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: nateglinide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes diagnosed at least 1 year before inclusion Blood glucose criteria must be met Microalbuminuria criteria must be met Exclusion Criteria: Pregnant or nursing females or females of childbearing potential not using a medically approved birth control method Blood glucose criteria outside the specified range Microalbuminuria criteria outside the specified range Serious cardiovascular events within the past 6 months Other protocol-defined exclusion criteria may apply

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: nateglinide|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in postprandial glomerular filtration rate at 12 weeks |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in fasting morning glomerular filtration rate at 12 weeks |  |  | 
| Change from baseline in postprandial renal plasma flow at 12 weeks |  |  | 
| Change from baseline in fasting morning renal plasma flow at 12 weeks |  |  | 
| Change from baseline in adjusted 2-hour postprandial glucose at 12 weeks |  |  | 
| Change in insulin AUC (0-240 minutes) at 12 weeks |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Type 2 diabetes, nateglinide
Traumatic Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs

Study Overview
=================
Brief Summary
-----------------
Oral antithrombotic medications (OAM) are used for the prevention and treatment of thrombotic disorders. Among hemorrhagic complications of OAMs, intracranial hemorrhage (ICH) may have particularly devastating consequences with high morbidity, disability and mortality rates. The efficacy and safety profiles of OAMs are generally assessed in randomized controlled trials (RCT), but included patients are often highly selected and may not be representative of users in everyday clinical practice in terms of follow-up routines, age, gender, drug compliance, and polypharmacy. Moreover, it is often unclear whether or not traumatic ICHs are registered and reported in RCTs. Drifts in indications and treatment criteria may also be seen in everyday practice and drug discontinuation due to precautionary concerns including compliance, fall risk and comorbidity may be forgotten. Collectively, these factors may lead to other and potentially higher traumatic ICH rates in general clinical use than reported in RCTs. The incidence rates of traumatic ICH in patients on OAMs in the general population remain unknown. In this nationwide registry based pharmacoepidemiological study we will investigate the incidence and case fatality of traumatic ICH in users of OAMs in Norway from 2008 through 2014.

Official Title
-----------------
Traumatic Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs: a Nationwide Pharmacoepidemiological Study

Conditions
-----------------
Intracranial Hemorrhage, Traumatic, Embolism and Thrombosis, Hematoma, Subdural, Intracranial

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: included in the Norwegian patient registry (NPR) and/or the Norwegian prescription database (NorPD) Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of intracranial hemorrhage requiring hospital admission | Age- and gender-adjusted comparisons of annual incidence rates will be carried out | at least 12 months following intracranial hemorrhage | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of fatal traumatic intercranial hemorrhage defined as death within 90 days of admission | Age- and gender-adjusted comparisons of annual incidence rates will be carried out. | 90 days | 
| overall survival following traumatic intracranial hemorrhage |  | 6 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fibrinolytic Agents, Adverse effects, Norway, Registries
Prevalence and Risk Factors for Pain and Related Adverse Reactions Among Breast Cancer Survivors on Aromatase Inhibitors

Study Overview
=================
Brief Summary
-----------------
We obtained the occurrence of pain sensation, pain mood, sleep, etc. during endocrine therapy in breast cancer patients through telephone follow-up, and analyzed risk factors through artificial intelligence

Official Title
-----------------
Doctor of Medical Sciences

Conditions
-----------------
Breast Cancer, Aromatase Inhibitors, Endocrine Therapy, Pain, Anxiety, Depression, Sleep

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Breast cancer survivors on aromatase inhibitors Exclusion Criteria: Advanced breast cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PAIN<br> | Other: No intervention<br>* No intervention<br>|
| NO PAIN<br> | Other: No intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence and risk factors for pain and related adverse reactions among breast cancer survivors on aromatase inhibitors |  | 2022-10 ---2023-03 |
PFO ACCESS Registry

Study Overview
=================
Brief Summary
-----------------
Closure of Patent Foramen Ovale with the AMPLATZER® PFO OCCLUDER in patients with at least two cryptogenic strokes due to presumed paradoxical embolism through a patent foramen ovale and who have failed conventional therapy.

Detailed Description
-----------------
The primary objective of the PFO Access Registry is to allow access to the AMPLATZER PFO Occluder in subjects with a PFO who have already experienced at least two cryptogenic strokes due to presumed paradoxical embolism through a patent foramen ovale and who have failed conventional drug therapy.

Official Title
-----------------
Patent Foramen Ovale Closure With the AMPLATZER PFO OCCLUDER in Patients With Recurrent Cryptogenic Stroke Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale Who Have Failed Conventional Drug Therapy

Conditions
-----------------
Patent Foramen Ovale, Stroke

Intervention / Treatment
-----------------
* Device: Device closure with the AMPLATZER PFO Occluder


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patent foramen ovale (PFO); recurrent cryptogenic stroke; failed antiplatelet/anticoagulant therapy Exclusion Criteria: International normalized ration (INR) outside of 2-3; intracardiac thrombus (subjects may be enrolled after resolution of thrombus)
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PFO, stroke
Measuring Droplets in Children

Study Overview
=================
Brief Summary
-----------------
This study will measure the size and quantity of respiratory particle production in children under a variety of conditions, including face coverings/masks and various common activities.

Official Title
-----------------
Measuring Droplets in Children

Conditions
-----------------
Droplet Spread

Intervention / Treatment
-----------------
* Device: Various commercially available face coverings


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Age 3 to 17 years Exclusion Criteria: Chronic neuromuscular conditions that affect respiration Tracheostomy tube Unable to wear a face mask

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Face covering use<br>Participants will be provided various commercially available face coverings | Device: Various commercially available face coverings<br>* Various commercially available face coverings<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Respiratory particle production |  | 2 hours |
Laparoscopic Cholecystectomy Care Protocol

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine compliance with the Prisma Health-Upstate Laparoscopic Cholecystectomy Perioperative Protocol.

Detailed Description
-----------------
Evidence based medicine calls for the application of scientific advances to clinical care. In an effort to address the most common complications of a surgical procedure, perioperative protocols have recently been created in an effort to apply best practices consistently and enhance the recovery from surgery. In addition to evaluating the validity of the protocol components themselves, it is valuable to measure compliance with said protocol. Failure to complete the steps of a care pathway may be caused by several reasons, and a study of application of these steps may help future efforts at standardization of care. The purpose of this study is to determine compliance with the Prisma Health-Upstate Laparoscopic Cholecystectomy Perioperative Protocol. Hospital inpatient data from patient charts, office charts, and hospital medical data systems of Prisma Health-Upstate System will be used to review the records of all patients age 18-75 years, inpatient and outpatient, who had surgery for choledocolithiasis between January 1, 2016 to April 1, 2017.

Official Title
-----------------
Compliance With Laparoscopic Cholecystectomy Care Protocol

Conditions
-----------------
Laparoscopic Cholecystectomy

Intervention / Treatment
-----------------
* Other: Protocol Compliance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients between the ages of 18 years and 75 years who had surgery for choledocholithiasis at Prisma Health-Upstate. Exclusion Criteria: Patients under 18 years of age and older than 75 years of age.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Protocol Compliance|Compliance with the Prisma Health-Upstate Laparoscopic Cholecystectomy Perioperative Protocol|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Protocol Compliance | Percent compliance with protocol components | 15 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of Stay | Post acute care unit length of stay will be measured in minutes | 15 months |
Study to Measure the Prevalence of Asynchrony In Mechanically Ventilated Patients

Study Overview
=================
Brief Summary
-----------------
This study will examine the prevalence of patient-ventilator asynchrony and its determinants. Mechanically ventilated trauma patients often experience asynchrony when their pattern of breathing does not match the triggering of a mechanical ventilator. Asynchrony is thought to be more common in delirious patients, patients with chronic lung disease and those who are heavily sedated. The study will examine the relationship between (1) delirium and sedation and (2) the prevalence of asynchrony in trauma patients.

Detailed Description
-----------------
This is a prospective observational study to determine the prevalence of patient/ventilator asynchrony in a cohort of trauma and surgical patients. There will be two 20-minute periods of observation. The first will be during the first 24 hours of mechanical ventilation and the second will take place when the patient is being weaned from the ventilator and is triggering half or more of all ventilator breaths. The study team will use computer-captured waveforms to determine the proportion of all breaths that are asynchronous. This proportion is the primary outcome variable of the study. The study hypothesis is that the proportion of asynchronous breaths is higher in patients with higher levels of sedation, as measured by the Richmond Agitation-Sedation Scale (RASS) and the Confusion Assessment Methods for the Intensive Care Unit (CAM-ICU). This hypothesis will be tested using repeated measures analysis of variance.

Official Title
-----------------
Prevalence of Patient Ventilator Asynchrony in Trauma and Surgical Patients

Conditions
-----------------
Patient/Ventilator Asynchrony

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Trauma or surgical diagnosis Patients requiring mechanical ventilation Exclusion Criteria: Patients with no spontaneous breathing efforts due to injury or chemical paralysis Patients with leaks in the patient ventilator system precluding evaluation of waveforms

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of asynchronous breaths |  | 20 minutes during first 24 hours on ventilation and 20 minutes during weaning phase | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
asynchrony, mechanical ventilation, blunt trauma
Effect of Sufentanil and Ropivacaine

Study Overview
=================
Brief Summary
-----------------
The investigators study the efficacy of epidural sufentanil/ropivacaine for analgesia labor in primiparas so as to decrease perinatal complications of analgesia labor.

Detailed Description
-----------------
A prospective study of 120 full-term parturients receiving labor analgesia were randomly assigned into 2 groups: the 0.5Sufen group (N=60), the 0.25Sufen group (N=60).

Official Title
-----------------
Effect of 0.5µg/ml Sufentanil and Ropivacaine Towards Pregnant Women and Fetus in Analgesia Labor

Conditions
-----------------
Anesthesia Complications

Intervention / Treatment
-----------------
* Drug: 0.25 sufentanil
* Drug: 0.5µg/ml sufentanil
* Drug: 0.1% ropivacaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients had regular prenatal examinations at the outpatient clinic; They were between 25 to 35 years of age) They had a gestational age ≥37 weeks and < 42 weeks; They had an estimated fetal weight ≥ 2,500 g and < 4,200 g. Exclusion Criteria: a history of spinal surgery, platelet count <100×109 /L , coagulation disorder, sensorimotor disorder of lower extremity, leg pain, puncture point infection, heart disease history, pulmonary disease, liver and renal function disorder and a history of neuropsychiatry drugs.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 0.5 sufentanil<br>0.5µg/ml sufentanil, 0.1% ropivacaine for 6ml/h | Drug: 0.5µg/ml sufentanil<br>* 0.5µg/ml sufentanil<br>* Other names: opiods;Drug: 0.1% ropivacaine<br>* 0.1% ropivacaine<br>* Other names: Local Anesthetics;|
| Experimental: 0.25 sufentanil<br>0.25µg/ml sufentanil, 0.1% ropivacaine for 6ml/h | Drug: 0.25 sufentanil<br>* with different dosage<br>* Other names: opiods;Drug: 0.1% ropivacaine<br>* 0.1% ropivacaine<br>* Other names: Local Anesthetics;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VAS(visual analog pain score) | comparison with two groups | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Epidural, Analgesia labor, Perinatal, anesthesia